96 related articles for article (PubMed ID: 3514807)
1. 13-cis retinoic acid treatment for myelodysplastic syndromes.
Picozzi VJ; Swanson GF; Morgan R; Hecht F; Greenberg PL
J Clin Oncol; 1986 Apr; 4(4):589-95. PubMed ID: 3514807
[TBL] [Abstract][Full Text] [Related]
2. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol.
Besa EC; Abrahm JL; Bartholomew MJ; Hyzinski M; Nowell PC
Am J Med; 1990 Dec; 89(6):739-47. PubMed ID: 2252043
[TBL] [Abstract][Full Text] [Related]
3. 13-cis-Retinoic acid treatment in patients with myelodysplastic syndrome.
Leoni F; Ciolli S; Longo G; Messori A; Ferrini PR
Acta Haematol; 1988; 80(1):8-12. PubMed ID: 3135696
[TBL] [Abstract][Full Text] [Related]
4. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes.
Ganser A; Seipelt G; Verbeek W; Ottmann OG; Maurer A; Kolbe K; Hess U; Elsner S; Reutzel R; Wörmann B
Leukemia; 1994 Mar; 8(3):369-75. PubMed ID: 7510354
[TBL] [Abstract][Full Text] [Related]
5. Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.
Clark RE; Smith SA; Jacobs A
J Clin Pathol; 1987 Jun; 40(6):652-6. PubMed ID: 3475292
[TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study.
Aul C; Runde V; Gattermann N
Blood; 1993 Nov; 82(10):2967-74. PubMed ID: 8219188
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes.
Gold EJ; Mertelsmann RH; Itri LM; Gee T; Arlin Z; Kempin S; Clarkson B; Moore MA
Cancer Treat Rep; 1983 Nov; 67(11):981-6. PubMed ID: 6580071
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.
Koeffler HP; Heitjan D; Mertelsmann R; Kolitz JE; Schulman P; Itri L; Gunter P; Besa E
Blood; 1988 Mar; 71(3):703-8. PubMed ID: 3278754
[TBL] [Abstract][Full Text] [Related]
9. Responses of hemopoietic precursors to 13-cis retinoic acid and 1,25 dihydroxyvitamin D3 in the myelodysplastic syndromes.
Swanson G; Picozzi V; Morgan R; Hecht F; Greenberg P
Blood; 1986 Apr; 67(4):1154-61. PubMed ID: 3513868
[TBL] [Abstract][Full Text] [Related]
10. 13-cis-retinoic acid in myelodysplastic syndromes.
Greenberg BR; Buzaid AC; Meyskens FL
J Clin Oncol; 1986 Aug; 4(8):1282. PubMed ID: 3525772
[No Abstract] [Full Text] [Related]
11. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
12. Absent clinical effects of retinoic acid and isoretinoin treatment in the myelodysplastic syndrome.
Hast R; Axdorph S; Laurén L; Reizenstein P
Hematol Oncol; 1989; 7(4):297-301. PubMed ID: 2737610
[TBL] [Abstract][Full Text] [Related]
13. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
[TBL] [Abstract][Full Text] [Related]
15. Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic syndrome: inhibition of growth of the patient's malignant monocytoid clone.
Abrahm J; Besa EC; Hyzinski M; Finan J; Nowell P
Blood; 1986 May; 67(5):1323-7. PubMed ID: 3457608
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid in the treatment of myelodysplastic syndromes.
Visani G; Tosi P; Manfroi S; Ottaviani E; Finelli C; Cenacchi A; Bendandi M; Tura S
Leuk Lymphoma; 1995 Oct; 19(3-4):277-80. PubMed ID: 8535219
[TBL] [Abstract][Full Text] [Related]
17. Differentiation therapy of myelodysplastic syndromes with retinoic acid.
Ohno R
Leuk Lymphoma; 1994 Aug; 14(5-6):401-9. PubMed ID: 7812199
[TBL] [Abstract][Full Text] [Related]
18. 13-cis retinoic acid treatment of myelodysplastic syndromes.
Kerndrup G; Bendix-Hansen K; Pedersen B; Ellegaard J; Hokland P
Leuk Res; 1987; 11(1):7-16. PubMed ID: 3027462
[TBL] [Abstract][Full Text] [Related]
19. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
[TBL] [Abstract][Full Text] [Related]
20. Use of differentiation-inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia.
Hoffman SJ; Robinson WA
Am J Hematol; 1988 Jun; 28(2):124-7. PubMed ID: 3293438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
